Despite a continuation of the stock market bull run, there were a bunch of underperformers this year, including Macy's, TripAdvisor, and Abiomed.
News & Analysis: Adamas Pharmaceuticals
Slowing growth for its flagship drug leads to analysts' downgrades.
Adamas Pharmaceuticals' valuation took yet another hit last month. Here's why.
Shares fall hard after the company reports good news. What's going on?
Adamas' steady march lower continued in September. Here's why.
Investors fret over the launch of the biotech's new Parkinson's disease drug Gocovri.
Potential competition has investors spooked.
Industry watchers are increasingly optimistic about this upstart's future.
Steven Cohen's Point72 Asset Management disclosed a big stake in the biotech, but be careful following the guru.
FDA approvals tend to make investors happy.
Better than expected fourth quarter results couldn't keep traders from dumping the company's stock.